AN2 Therapeutics, Inc. (ANTX) Ownership
ANTX ownership summary
as of October 17, 2026- Institutions
- 76.9% of shares outstanding
- Insiders
- 15.99% of shares outstanding
- Shares outstanding
- 37.7M
- Float
- 22.3M shares available to trade
- Short interest
- 7.84% 2.5M shares short
- Days to cover
- 10.71 short interest up 3.9% vs prior month
- Institutions 76.88%
- Insiders 15.99%
- Other investors 7.13%
ANTX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vivo Capital, LLC | 8.36% | 3.2M | $10.7M | — | June 30, 2026 |
| 2 | COMMODORE CAPITAL LP | 7.77% | 2.9M | $9.9M | +599,967 (+25.7%) | June 30, 2026 |
| 3 | Millennium Management LLC | 6.14% | 2.3M | $7.8M | +96,190 (+4.3%) | June 30, 2026 |
| 4 | BlackRock Inc | 4.41% | 1.7M | $5.6M | +1.3M (+422.5%) | June 30, 2026 |
| 5 | Spruce Street Capital LP | 4.40% | 1.7M | $5.6M | — | June 30, 2026 |
| 6 | Almitas Capital LLC | 3.89% | 1.5M | $5.0M | −10,000 (−0.7%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 3.28% | 1.2M | $4.2M | +227,627 (+22.5%) | June 30, 2026 |
| 8 | Adage Capital Partners Gp LLC | 2.65% | 1.0M | $3.4M | — | June 30, 2026 |
| 9 | Citadel Advisors Llc | 2.52% | 952K | $3.2M | +796,758 (+513.2%) | June 30, 2026 |
| 10 | Boxer Capital Management, LLC | 1.98% | 749K | $2.5M | — | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 1.85% | 698K | $2.4M | +411,259 (+143.5%) | June 30, 2026 |
| 12 | SummitTX Capital, L.P | 1.58% | 597K | $2.0M | +597,453 (0.0%) | June 30, 2026 |
| 13 | Balyasny Asset Management LLC | 1.47% | 556K | $1.9M | +556,027 (0.0%) | June 30, 2026 |
| 14 | Stonepine Capital Management Llc | 1.46% | 552K | $1.9M | −162,153 (−22.7%) | June 30, 2026 |
| 15 | Ameriprise Financial Inc | 1.42% | 537K | $1.8M | −159,117 (−22.9%) | June 30, 2026 |
| 16 | Sio Capital Management, LLC | 1.40% | 530K | $1.8M | −127,267 (−19.4%) | June 30, 2026 |
| 17 | Ally Bridge Group (NY) LLC | 1.39% | 526K | $1.8M | — | June 30, 2026 |
| 18 | Prosight Management, LP | 1.26% | 475K | $1.6M | −41,116 (−8.0%) | June 30, 2026 |
| 19 | Woodline Partners LP | 1.22% | 460K | $1.6M | −533,866 (−53.7%) | June 30, 2026 |
| 20 | Aldebaran Capital LLC | 0.97% | 367K | $1.2M | −4,335 (−1.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 8 holders added 4.6M shares and 7 cut 1.0M.
ANTX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.26% | 853K | $2.9M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.78% | 670K | $2.3M | −7,744 (−1.1%) | September 30, 2026 |
| 3 | MEDICAL BioHealth EUR Acc | 1.68% | 632K | $2.1M | +134 (+0.0%) | August 31, 2026 |
| 4 | apo Medical Opportunities R | 0.88% | 331K | $1.1M | — | August 31, 2026 |
| 5 | Fidelity Small Cap Index | 0.77% | 289K | $977,594 | +2,122 (+0.7%) | July 31, 2026 |
| 6 | iShares Russell 2000 Value ETF | 0.59% | 223K | $753,794 | +338 (+0.2%) | September 30, 2026 |
| 7 | Vanguard Russell 2000 ETF | 0.40% | 151K | $511,093 | +3,000 (+2.0%) | August 31, 2026 |
| 8 | Fidelity Extended Market Index | 0.25% | 96K | $324,466 | −516 (−0.5%) | August 31, 2026 |
| 9 | iShares Micro-Cap ETF | 0.22% | 82K | $277,887 | −567 (−0.7%) | September 30, 2026 |
| 10 | RIM Global Bioscience EUR | 0.19% | 70K | $236,600 | — | June 30, 2026 |
| 11 | Schwab Small Cap Index | 0.17% | 64K | $217,064 | — | August 31, 2026 |
| 12 | EA Bridgeway Ultra-Small Company Mkt ETF | 0.15% | 58K | $196,750 | — | September 30, 2026 |
| 13 | Fidelity Total Market Index | 0.15% | 58K | $195,776 | — | August 31, 2026 |
| 14 | iShares Russell 2000 Small-Cap Idx Instl | 0.13% | 49K | $167,209 | — | August 31, 2026 |
| 15 | Fidelity Series Total Market Index | 0.13% | 49K | $163,937 | +3,455 (+7.7%) | August 31, 2026 |
| 16 | Goldman Sachs ActiveBeta® US SmCp Eq ETF | 0.11% | 41K | $138,337 | — | September 30, 2026 |
| 17 | Nuveen Small Cap Blend Idx R6 | 0.09% | 35K | $119,426 | — | August 31, 2026 |
| 18 | Dimensional US Small Cap ETF | 0.09% | 35K | $119,294 | — | September 30, 2026 |
| 19 | Fidelity Small Cap Value Index | 0.09% | 34K | $114,920 | +1,093 (+3.3%) | July 31, 2026 |
| 20 | iShares Russell 2000 Growth ETF | 0.08% | 30K | $101,032 | −38 (−0.1%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ANTX insider transactions
latest 14| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | Sarah Joanne Williams | Sell | $1.06 | 327 | $347 |
| 2026-01-06 | Joshua M Eizen | Sell | $1.01 | 6,931 | $7,000 |
| 2026-01-06 | Lucy Day | Sell | $1.01 | 5,512 | $5,567 |
| 2026-01-06 | Sanjay Chanda | Sell | $1.01 | 5,956 | $6,016 |
| 2026-01-06 | Stephen David Prior | Sell | $1.01 | 2,858 | $2,887 |
| 2026-01-05 | Joshua M Eizen | Sell | $1.00 | 17,923 | $17,923 |
| 2026-01-05 | Lucy Day | Sell | $1.00 | 3,295 | $3,295 |
| 2026-01-05 | Sanjay Chanda | Sell | $1.00 | 3,295 | $3,295 |
| 2026-01-05 | Stephen David Prior | Sell | $1.00 | 3,604 | $3,604 |
| 2025-11-04 | Joshua M Eizen | Sell | $1.14 | 2,819 | $3,214 |
| 2025-11-04 | Stephen David Prior | Sell | $1.14 | 765 | $872 |
| 2025-05-30 | Braden Michael Leonard | Sell | $1.01 | 432,000 | $436,320 |
| 2025-05-28 | Braden Michael Leonard | Sell | $1.16 | 2,100,000 | $2.4M |
| 2025-05-28 | Margaret M Fitzpatrick | Buy | $1.18 | 8,610 | $10,160 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ANTX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ANTX
Institutional investors own 76.9% of AN2 Therapeutics's shares and insiders 15.99%. The largest holder is Vivo Capital, LLC with 8.36% of the shares (3.2M), as of June 30, 2026. Among the top 20 institutions, 8 added shares and 7 reduced their stake in the latest filings. Short interest is 7.84% of the float, or 10.71 days of average trading volume. The share count rose 907.2% since 2020.
Related: ANTX analyst forecast, ANTX key metrics. See the ANTX stock overview for the latest quote and news.
ANTX ownership FAQ
Who owns the most AN2 Therapeutics stock?
The largest shareholders of AN2 Therapeutics are Vivo Capital, LLC (8.36%), COMMODORE CAPITAL LP (7.77%), Millennium Management LLC (6.14%), BlackRock Inc (4.41%), Spruce Street Capital LP (4.40%).
What percentage of AN2 Therapeutics is owned by institutions?
Institutions hold 76.9% of AN2 Therapeutics's shares outstanding; insiders hold 15.99%.
Which funds own AN2 Therapeutics?
The largest fund holders of AN2 Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.26%), iShares Russell 2000 ETF (1.78%), MEDICAL BioHealth EUR Acc (1.68%), apo Medical Opportunities R (0.88%), Fidelity Small Cap Index (0.77%).
What is AN2 Therapeutics's short interest?
2.5M shares of AN2 Therapeutics were sold short, 7.84% of the float; at the average daily volume it would take 10.71 days to cover.
Are insiders buying or selling AN2 Therapeutics?
Of the latest 14 reported insider transactions in AN2 Therapeutics (since May 28, 2025), 1 were purchases and 13 were sales.
How many shares of AN2 Therapeutics are outstanding?
AN2 Therapeutics has 37.7M shares outstanding, of which 22.3M are in the public float.